FindTrial
Sign In

An observational clinical study of the safety and efficacy of surufatinib in patients with advanced non-small cell lung cancer

An observational clinical study of the safety and efficacy of surufatinib in patients with advanced non-small cell lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400082982
Enrollment
Unknown
Registered
2024-04-12
Start date
2024-04-14
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC

Interventions

Grouping based on the medication of subjects:None

Sponsors

Navy Anqing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed with advanced non-small cell lung cancer; (2) physician-evaluated patients who could benefit from the antiangiogenic targeted agent surfatinib; (3) Patients voluntarily participated in the project and signed the informed consent.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
PFS;—

Secondary

MeasureTime frame
OS;ORR;DCR;—

Countries

China

Contacts

Public ContactHuan Chen

Navy Anqing Hospital

Chenh5751@yeah.net+86 189 0556 5751

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026